Novartis Ag (NVS) Receivables Refunds (2016 - 2026)

Novartis Ag's Receivables Refunds history runs 11 years deep, the most recent figure standing at $216.0 million for Q1 2026.

• In Q1 2026, Receivables Refunds rose 67.44% year-over-year to $216.0 million; the TTM figure through Mar 2026 stood at $216.0 million (up 67.44% YoY), while the FY2025 annual figure was $205.0 million, up 54.14% from the prior year.
• Receivables Refunds came in at $216.0 million for Q1 2026 at Novartis Ag, up from $205.0 million in the prior quarter.
• In the past five years, Receivables Refunds ranged from a high of $426.0 million in Q4 2023 to a low of $120.0 million in Q2 2025.
• A 5-year average of $245.5 million and a median of $258.0 million in 2022 frame the typical range for Receivables Refunds.
• Across the five-year window, Receivables Refunds tumbled 68.78% in 2024 and soared 67.44% in 2026, its largest moves.
• Novartis Ag's Receivables Refunds stood at $268.0 million in 2022, then soared by 58.96% to $426.0 million in 2023, then sank by 68.78% to $133.0 million in 2024, then surged by 54.14% to $205.0 million in 2025, then advanced by 5.37% to $216.0 million in 2026.
• According to Business Quant data, Receivables Refunds over the past three periods registered $216.0 million, $205.0 million, and $140.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison